Nøkkelinformasjon info chevron_right

Viktig informasjon i saken hentes i sanntid direkte fra EPO sitt register (European Patent Register), slik at du enkelt og raskt får oversikt i saken.
Beskrivelse Verdi
Saken / databasen er sist oppdatert info  
Tittel HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
Status
Hovedstatus
Detaljstatus 		I kraft info EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
Patentnummer NO/EP3590517
Europeisk (EP) publiserings nummer EP3590517
EP levert
EP søknadsnummer 19188885.8
EP meddelt
Avdelt fra EP3338781
Avdelt til EP3851107;
Prioritet 2012.05.25, US 201261651669 P, .... se mer/flere nedenfor
Sakstype Europeisk
Løpedag
Utløpsdato
Allment tilgjengelig
Validert i Norge
Innehaver Corcept Therapeutics Incorporated (US)
Oppfinner HUNT, Hazel (GB) .... se mer/flere nedenfor
Fullmektig ZACCO NORWAY AS (NO)
Lenke til European patent Register Informasjon i saken, dokumenter og patentfamilie
Patentfamilie Se i Espacenet

Sammendrag og figur info chevron_right

EPO translation logo


Se forsidefigur og sammendrag i Espacenet

Beskrivelse og krav info chevron_right

T3

Beskrivelse

Krav

Patentkrav1. Farmasøytisk sammensetning omfattende en forbindelse av formel (I) og en farmasøytisk akseptabel eksipient, for anvendelse i en fremgangsmåte for behandling av en lidelse ved modulering av en glukokortikoidreseptor, hvor lidelsen er Cushings syndrom, hyperkortisolemi, hyperglykemi, diabetes, hypertensjon eller kardiovaskulære sykdommer, idet forbindelsen har formelen:hvorR1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper som hver uavhengig velges fra R1a; hver R1a velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, -CN, N-oksid, C3-8-sykloalkyl og C3-8-heterosykloalkyl;ring J velges fra gruppen bestående av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvor heterosykloalkylog heteroarylringene har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S; hver R2 velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, C1-6-alkyl-C1-6-alkoksy, -CN, -OH, -NR2aR2b, -C(O)R2a, -C(O)OR2a, -C(O)NR2aR2b, -SR2a, -S(O)R2a, -S(O)2R2a, C3-8-sykloalkyl og C3-8-heterosykloalkyl, hvor heterosykloalkylgruppene valgfritt substitueres med 1-4 R2c-grupper; alternativt kombineres to R2-grupper som er forbundet med det samme karbon, for å danne en okso-gruppe (=O);alternativt kombineres to R2-grupper for å danne en heterosykloalkylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer som hvert uavhengig velges fra gruppen bestående av N, O og S, hvor heterosykloalkylringen valgfritt substitueres med fra 1 til 3 R2d-grupper;R2a og R2b velges hver uavhengig fra gruppen bestående av hydrogen og C1-6-alkyl;hver R2c velges uavhengig fra gruppen bestående av hydrogen, halogen, hydroksy, C1-6-alkoksy, C1-6-haloalkoksy, -CN og -NR2aR2b;hver R2d velges uavhengig fra gruppen bestående av hydrogen og C1-6-alkyl, eller to R2d-grupper som er festet til det samme ringatom, kombineres for å danne (=O);R3 velges fra gruppen bestående av fenyl og pyridyl, hver valgfritt substituert med 1-4 R3a-grupper;hver R3a velges uavhengig fra gruppen bestående av hydrogen, halogen og C1-6-haloalkyl;n i senket skrift er et heltall fra 0 til 3;eller et salt derav.2. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor R1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 4 heteroatomer hvert uavhengig valgt fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper hver uavhengig valgt fra R1a;hver R1a velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, -CN, C3-8-sykloalkyl og C3-8-heterosykloalkyl;ring J velges fra gruppen bestående av en sykloalkylring, en heterosykloalkylring, en arylring og en heteroarylring, hvor heterosykloalkyl- og heteroarylringene har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer hvert uavhengig valgt fra gruppen bestående av N, O og S;hver R2 velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, -CN, NR2aR2b, C3-8-sykloalkyl og C3-8-heterosykloalkyl, hvor heterosykloalkylgruppene valgfritt substitueres med 1-4 R2c-grupper;R2a og R2b velges hver uavhengig fra gruppen bestående av hydrogen og C1-6-alkyl; hver R2c velges uavhengig fra gruppen bestående av hydrogen, halogen, hydroksy, C1-6-alkoksy, C1-6-haloalkoksy, -CN og NR2aR2b; R3 velges fra gruppen bestående av fenyl og pyridyl, hver valgfritt substituert med 1-4 R3a-grupper;hver R3a velges uavhengig fra gruppen bestående av hydrogen, halogen og C1-6-haloalkyl; ogn i senket skrift er et heltall fra 0 til 3.3. Farmasøytisk sammensetning for anvendelse ifølge krav 1 eller 2, hvor:(a) R1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer hvert uavhengig valgt fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper hver uavhengig valgt fra R1a; hver R1a velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, C1-6-haloalkyl og C1-6-alkoksy;ring J velges fra gruppen bestående av tetrahydrofuran, fenyl og pyridyl; hver R2 velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, -CN, NR2aR2b, C3-8-sykloalkyl og C3-8-heterosykloalkyl;R2a og R2b velges hver uavhengig fra gruppen bestående av hydrogen og C1-6-alkyl;R3 velges fra gruppen bestående av fenyl og pyridyl; R3a er F; ogn i senket skrift er 0 eller 1; eller(b) R1 er en heteroarylring som har fra 5 til 6 ringelementer og fra 1 til 3 heteroatomer hvert uavhengig valgt fra gruppen bestående av N, O og S, valgfritt substituert med 1-4 grupper hver uavhengig valgt fra R1a; hver R1a velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, C1-6-haloalkyl og C1-6-alkoksy;ring J velges fra gruppen bestående av fenyl og pyridyl; hver R2 velges uavhengig fra gruppen bestående av hydrogen, halogen, C1-6-haloalkyl, CN og C5-6-heterosykloalkyl;R3 velges fra gruppen bestående av fenyl og pyridyl; og R3a er F. 4. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 3, hvor R1 velges fra gruppen bestående av(a) pyrrol, pyrazol, imidazol, triazol, tetrazol, furan, oksazol, isoksazol, oksadiazol, tiofen, tiazol, isotiazol, tiadiazol, pyridin, pyrazin, pyrimidin og pyridazin;(b) 2-pyrrol, 3-pyrrol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3,-triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 1,2,3,4-tetrazol-1-yl, 1,2,3,4,tetrazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 3-isoksazol, 4-isooksazol, 5-isooksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 3-isotiazol, 4-isotiazol, 5-isotiazol, 1,2,3-tiadiazol-4-yl, 1,2,3-tiadiazol-5-yl, 1,2,4-tiadiazol-3-yl, 1,2,4-tiadiazol-5-yl, 1,2,5-tiadiazol-3-yl, 1,3,4-tiadiazol-2-yl, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin, 6-pyrimidin, 3-pyridazin, 4-pyridazin, 5-pyridazin og 6-pyrdazin;(c) pyrazol, imidazol, triazol, furan, oksazol, oksadiazol, tiofen, tiazol, pyridin, pyrazin og pyrimidin; eller(d) 1-pyrazol, 3-pyrazol, 4-pyrazol, 5-pyrazol, 2-imidazol, 4-imidazol, 5-imidazol, 1,2,3-triazol-4-yl, 1,2,3, -triazol-5-yl, 1,2,4-triazol-3-yl, 1,2,4-triazol-5-yl, 2-furan, 3-furan, 2-oksazol, 4-oksazol, 5-oksazol, 1,2,4-oksadiazol-3-yl, 1,2,4-oksadiazol-5-yl, 1,2,5-oksadiazol-3-yl, 1,3,4-oksadiazol-2-yl, 2-tiofen, 3-tiofen, 2-tiazol, 4-tiazol, 5-tiazol, 2-pyridin, 3-pyridin, 4-pyridin, pyrazin, 2-pyrimidin, 4-pyrimidin, 5-pyrimidin og 6-pyrimidin.5. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1, 2 og 4, hvor hver R1a velges uavhengig fra gruppen bestående av hydrogen, C1-6-alkyl, C1-6-haloalkyl, C1-6-alkoksy og C3-8-heterosykloalkyl. 6. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 5, hvor hver R1a velges uavhengig fra gruppen bestående av hydrogen, metyl, etyl, trifluormetyl og metoksy.7. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1, 2 og 4 til 6, hvor ring J velges fra gruppen bestående av(a) heterosykloalkyl, aryl og heteroaryl;(b) aryl og heteroaryl; eller(c) fenyl, pyridin, imidazol, pyrazol, triazol, tetrazol, tiadiazol, isotiazol, isoksazol, sykloheksyl, tetrahydrofuran og tetrahydro-2H-pyran.8. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 7, hvor ring J er fenyl eller pyridyl.9. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 og 4 til 8, hvor hver R2 velges uavhengig fra gruppen bestående av (a) hydrogen, C1-6-alkyl, halogen, C1-6-haloalkyl, C1-6-alkoksy, C1-6-haloalkoksy, C1-6-alkyl-C1-6-alkoksy, -CN, NR2aR2b, C(O)OR2a, S(O)2R2a, C3-8-sykloalkyl eller C3-8-heterosykloalkyl, hvor heterosykloalkylgruppen har 5-6 ringelementer og 1 til 2 heteroatomer; eller(b) hydrogen, metyl, etyl, propyl, isopropyl, F, Cl, -CF3, CH2OMe, OMe, OCHF2, -CN, -NMe2, -C(O)OH, -C(O)NMe2, -S(O)2Me, pyrrolidin, piperidin eller morfolin.10. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 9, hvor R3 er 4-F-fenyl.11. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor forbindelsen velges fra gruppen bestående av:(R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((6-klorpyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-3-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyl-1,3,4-oksadiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(furan-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiofen-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(oksazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrimidin-2-yl)metanon,(R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon, (R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metoksypyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-fluorbenzyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,((4aR)-1-(4-fluorfenyl)-6-((((R/S)-tetrahydrofuran-2-yl)metyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(o-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-etylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-metoksyfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-4-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((6-metoksypyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((tetrahydro-2H-pyran-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-(sykloheksylsulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((3,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((6-morfolinopyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-4-(((1-(4-fluorfenyl)-4a-(tiazol-2-karbonyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)metyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-1,2,4-triazol-5-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyrazin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-fluropyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metoksypyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-5-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-fluropyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((6-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, ((R)-1-(4-fluorfenyl)-6-((6-((R)-3-fluorpyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-(pyrrolidin-1-yl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-(piperidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-(pyrrolidin-1-yl)pyridin-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(6-((4-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-metoksy-3-metylfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3-klor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3-fluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((2-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(6-((4-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetoksy)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(6-((3-(difluormetoksy)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,5-dimetylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-metylpyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3-klor-4-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3,5-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,(R)-(1-(4-fluorfenyl)-6-((3-(metoksymetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4ayl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2,3,4-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3 -yl)sulfonyl)-4,4a, 5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((4-fluor-3-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((4-metyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oksazin-7-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((2,3-dihydrobenzofuran-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-5-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylindolin-2-on,(R)-(1-(4-fluorfenyl)-6-((3-(metylsulfonyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(6-((1,3-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((2,3-dihydrobenzo[b][1,4]dioksin-6-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-3-((4a-(4-etylpikolinoyl)-1-(4-fluorfenyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(4-etylpyridin-2-yl)(1-(4-fluorfenyl)-6-((6-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4ayl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-(4-metylpikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzosyre,(R)-(6-((3,5-dimetylisoksazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-fenyl-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)pyridin-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-(trifluormetyl)pyridin-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((4-klor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3-klor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(2-(pyrrolidin-1-yl)pyridin-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3 -yl)sulfonyl)-4,4a, 5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((5-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-3-((1-(4-fluorfenyl)-4a-(4-(trifluormetyl)pikolinoyl)-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)benzonitril,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1,5-dimetyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-3-(trifluormetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, (R)-(1-(4-klorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-1-(4-(trifluormetyl)fenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,(R)-(6-((1,2-dimetyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1,2-dimetyl-1H-imidazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-imidazol-2-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-imidazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-(2-metoksyetyl)-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-pyrazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-metyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((2-etyl-2H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-1,2,3-triazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-1,2,3-triazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-propyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-isopropyl-1H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-metoksyfenyl)-6-((3-fluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-fluor-4-metylfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-(fenylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-klorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metylpyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(6-metylpyridin-2-yl)metanon,(R)-(6-((4-fluor-3-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3,4,5-trifluorfenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-metyltiazol-2-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(6-((4-klor-3-fluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(6-((1,3-dimetyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-propyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-tosyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-(m-tolylsulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(1-metyl-1H-imidazol-2-yl)metanon, (R)-3-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-N,N-dimetylbenzamid,(R)-(6-((1-etyl-1H-pyrazol-4-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-pyridin-2-yl(1-(pyridin-3-yl)-6-((3-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)metanon, (R)-(6-((3,4-diklorfenyl)sulfonyl)-1-fenyl-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(3,4-difluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((3,5-difluor-4-metoksyfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(6-((6-(dimetylamino)pyridin-3-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-5-((1-(4-fluorfenyl)-4a-pikolinoyl-4a,5,7,8-tetrahydro-1H-pyrazolo[3,4-g]isokinolin-6(4H)-yl)sulfonyl)-1-metylpyridin-2(1H)-on,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon og(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon,eller salter derav.12. Farmasøytisk sammensetning for anvendelse ifølge krav 1, hvor forbindelsen velges fra gruppen bestående av:(R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((4-(trifluormetyl)fenyl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon, (R)-(6-((3,4-difluorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon,(R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-2-yl)metanon,(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(5-metyltiazol-2-yl)metanon,(R)-(6-((3-fluor-4-(trifluormetyl)fenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-3-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, (R)-(1-(4-fluorfenyl)-6-((1-metyl-1H-pyrazol-5-yl)sulfonyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon,(R)-(6-((1-etyl-1H-pyrazol-5-yl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(4-(trifluormetyl)pyridin-2-yl)metanon, eller(R)-(6-((3,4-diklorfenyl)sulfonyl)-1-(4-fluorfenyl)-4,4a,5,6,7,8-heksahydro-1H-pyrazolo[3,4-g]isokinolin-4a-yl)(tiazol-4-yl)metanon.13. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 12, hvor lidelsen er Cushings syndrom.14. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 12, hvor lidelsen er hyperkortisolemi.15. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 12, hvor lidelsen er hyperglykemi og/eller diabetes.16. Farmasøytisk sammensetning for anvendelse ifølge et hvilket som helst av kravene 1 til 12, hvor lidelsen er hypertensjon eller kardiovaskulær lidelse.
Hva betyr A1, B, B1, C osv? info

Klasser info chevron_right

Innehaver(e) info chevron_right

Innehaver i EP:
Corcept Therapeutics Incorporated
149 Commonwealth Drive Menlo Park, CA 94025 US

Oppfinner(e) info chevron_right

HUNT, Hazel
Edenderry House Bracken Close Storrington West Sussex GB
JOHNSON, Tony
8/9 Spire Green Centre Flex Meadow Harlow Essex GB
RAY, Nicholas
8/9 Spire Green Centre Flex Meadow Harlow Essex GB
WALTERS, Iain
BioCity Pennyfoot Street Nottingham Nottinghamshire NG1 1GF GB

Fullmektig info chevron_right

Fullmektig i Norge:
ZACCO NORWAY AS
Postboks 488 0213 OSLO NO ( OSLO kommune, Oslo fylke )

Org.nummer: 982702887
Din referanse: V53063NO00
  • Foretaksnavn:
  • Foretaksform:
  • Næring:
  • Forretningsadresse:
     

Kilde: Brønnøysundregistrene
Fullmektig i EP:
J A Kemp LLP
80 Turnmill Street London EC1M 5QU GB

Prioritet info chevron_right

2012.05.25, US 201261651669 P

2012.08.20, US 201261691083 P

2012.10.19, US 201261715907 P

2013.02.01, US 201361759520 P

2013.03.14, US 201361781629 P

Anførte dokumenter info chevron_right

WO-A1-2012/027702 (B1)

WO-A1-2005/087769 (B1)

Sakshistorikk info chevron_right

Statushistorie

Liste over statusendringer i sakshistorikk
Hovedstatus Beslutningsdato, detaljstatus
EP patent gjort gjeldende i Norge EP patent besluttet gjeldende i Norge
EP under behandling Forespørsel om å gjøre EP patent gyldig er mottatt

Korrespondanse

expand_more file_download  
Liste over sakshistorikk og korrespondanse
Dato Type korrespondanse Journal beskrivelse
Innkommende EP Publiseringsdokument fra EPO
19-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
18-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
17-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
16-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
15-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
14-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
13-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
12-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
11-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
10-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
09-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
08-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
07-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
06-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
05-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Innkommende EP Publiseringsdokument fra EPO
04-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Utgående EP Registreringsbrev (3210) (PTEP3590517)
03-01 Brev UT EP Registreringsbrev (3210) (PTEP3590517)
Innkommende Søknadsskjema Patent
01-01 Søknadsskjema Patent Søknadsskjema Patent
01-02 Hovedbrev NO_Validation_Request_May_26,_2021_113673
01-03 Fullmakt Norway Powers of Attorney N404237EP-B.._692386
01-04 EP oversettelse V53063NO00-claims-NO
Innkommende EP Publiseringsdokument fra EPO
02-01 EP Publiseringsdokument fra EPO EP Publiseringsdokument fra EPO
Informasjon om ikke tilgjengelige dokumenter

Betaling info chevron_right

Til betaling:

Beskrivelse Forfallsdato Beløp Status
Årsavgift expand_less Ikke betalt
Årsavgift 13. avg. år (EP) 5460,0 Totalbeløp 5460,0   Gå til betaling

Betalingshistorikk:

Liste av betalinger
Beskrivelse / Fakturanummer Betalingsdato Beløp Betaler Status
Årsavgift 12. avg. år (EP) 2024.05.08 5010 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 11. avg. år (EP) 2023.05.10 3500 CPA GLOBAL LIMITED Betalt og godkjent
Årsavgift 10. avg. år (EP) 2022.05.10 3200 CPA GLOBAL LIMITED Betalt og godkjent
32108438 expand_more 2021.06.24 5500 ZACCO NORWAY AS Betalt
Årsavgift 9. avg. år (EP) 2021.05.11 2850 CPA GLOBAL LIMITED Betalt og godkjent
Denne oversikten kan mangle informasjon, spesielt for eldre saker, om tilbakebetaling, internasjonale varemerker og internasjonale design.

Publikasjon(er) info chevron_right

Lenker til publikasjoner og Norsk Patenttidende (søkbare tekstdokumenter)

Oversettelse av europeisk patentskrift
Allment tilgjengelig patentsøknad
Norsk Patenttidende - ved meddelelse
Nye digitale Norske Tidende, nyhet om tjenesten ved lansering
Om Norske Tidende
Hva betyr A1, B, B1, C osv? info
Kapitler uten data er fjernet. Melding opprettet: 27.04.2025 18:26:19